Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study

被引:0
作者
Young Mi Seol
Hyo Jeong Kim
Young Jin Choi
Eun Mi Lee
Yang Soo Kim
Sung Yong Oh
Su Jin Koh
Jin Ho Baek
Won Sik Lee
Young Don Joo
Hyun Gi Lee
Eun Young Yun
Joo Seop Chung
机构
[1] Pusan National University Hospital Medical Research Institute,Division of Hemato
[2] Kosin University Gospel Hospital,Oncology, Department of Internal Medicine
[3] Dong-A University College of Medicine,Division of Hemato
[4] University of Ulsan College of Medicine,Oncology, Department of Internal Medicine
[5] Inje University College of Medicine,Division of Hemato
[6] Inje University College of Medicine,Oncology, Department of Internal Medicine, Dong
[7] Pusan National University Hospital Medical Research Institute,A University Hospital
来源
Supportive Care in Cancer | 2016年 / 24卷
关键词
CINV; Transdermal granisetron; Palonosetron;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:945 / 952
页数:7
相关论文
共 53 条
[11]  
Sato S(1994)Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 12 1050-1057
[12]  
Balfour JA(2009)Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting J Oncol Pharm Pract 15 223-231
[13]  
Goa KL(2011)Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study Support Care Cancer 19 1609-1617
[14]  
Hasler WL(2006)A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann Oncol 17 1441-1449
[15]  
Hesketh PJ(2003)Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2473-2482
[16]  
Forni C(2004)Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose ranging clinical study Ann Oncol 15 330-337
[17]  
Ferrari S(2003)Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 1570-1577
[18]  
Loro L(2011)Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis Support Care Cancer 19 823-832
[19]  
Gralla RJ(2001)Anti-emetics for cancer chemotherapy induced emesis: potential of alternative delivery systems Drugs 61 1553-1562
[20]  
Osoba D(undefined)undefined undefined undefined undefined-undefined